LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence

INTRODUCTION: Methamphetamine dependence is a growing public health concern. There is currently no pharmacotherapy approved for methamphetamine dependence. Lisdexamfetamine (LDX) dimesylate, used in the treatment of attention-deficit hyperactivity disorder and binge eating disorder, has potential as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezard, Nadine, Dunlop, Adrian, Hall, Michelle, Ali, Robert, McKetin, Rebecca, Bruno, Raimondo, Phung, Nghi, Carr, Andrew, White, Jason, Clifford, Brendan, Liu, Zhixin, Shanahan, Marian, Dolan, Kate, Baker, Amanda L, Lintzeris, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Addiction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059315/
https://www.ncbi.nlm.nih.gov/pubmed/30030312
http://dx.doi.org/10.1136/bmjopen-2017-020723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059315/
https://www.ncbi.nlm.nih.gov/pubmed/30030312
http://dx.doi.org/10.1136/bmjopen-2017-020723

Ejemplares similares